MICE models: Superior to the HERG model in predicting torsade de pointes

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Kramer, James ^a   Obejero Paz, Carlos A ^a   Myatt, Glenn ^b   Kuryshev, Yuri A ^a   Bruening Wright, Andrew ^a   Verducci, Joseph S ^c   Brown, Arthur M ^a  

^a ChanTest Corporation   (United States)

^b Leadscope   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERG1 POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG;

ARTICLE; HUMAN; PATCH CLAMP TECHNIQUE; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTIVE VALUE; THEORETICAL MODEL; TORSADE DES POINTES; TORSADES DE POINTES;

ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; MODELS, THEORETICAL; PATCH-CLAMP TECHNIQUES; PREDICTIVE VALUE OF TESTS; TORSADES DE POINTES;

EID: 84880116735     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep02100     Document Type: Article

References (30)

1. S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals (October 2005).
2. Sanguinetti, M. C., Jiang, C., Curran, M. E. & Keating, M. T. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell. 81, 299-307 (1995).
3. Roy, M., Dumaine, R. & Brown, A. M. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation. 94, 817-823 (1996). (Pubitemid 26289240)
4. Suessbrich, H., Waldegger, S., Lang, F. & Busch, A.E.Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett. 385, 77-80 (1996). (Pubitemid 26153472)
5. Sager, P. T. Key clinical considerations for demonstrating the utility of preclinical models to predict clinical drug-induced torsades de pointes. Br. J. Pharmacol. 154, 1544-1549 (2008).
6. Gintant, G. An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation. Pharmacol. Ther. 129, 109-119 (2011).
7. De Bruin, M. L., Pettersson, M., Meyboom, R. H., Hoes, A. W. & Leufkens, H. G. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur. Heart. J. 6, 590-597 (2005). (Pubitemid 40461101)
8. Zhang, S., Zhou, Z., Gong, Q., Makielski, J. C. &January, C. T. Mechanism of block and identification of the verapamil binding domain toHERG potassium channels. Circ. Res. 84, 989-998 (1999). (Pubitemid 29227678)
9. Bril, A. et al. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. J. Pharmacol. Exp. Ther. 276, 637-646 (1996). (Pubitemid 126660502)
10. Martin, R. L. et al. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J. Cardiovasc. Pharmacol. 43, 369-379 (2004). (Pubitemid 38270603)
11. Lacerda, A. E., Kuryshev, Y. A., Yan, G. X., Waldo, A. L. & Brown, A. M. Vanoxerine: cellular mechanism of a new antiarrhythmic. J. Cardiovasc. Electrophysiol. 21, 301-310 (2010).
12. Mirams, G. R. et al. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovasc. Res. 91, 53-61 (2011).
13. Hanson, L. A. et al. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation. J. Pharmacol. Toxicol. Methods. 54, 116-129 (2006). (Pubitemid 44293425)
14. Redfern, W. S. et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32-45 (2003). (Pubitemid 36351620)
15. Kirsch, G. E. et al. Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J. Pharmacol. Toxicol. Methods. 50, 93-101 (2004). (Pubitemid 39286321)
16. Peng, S., Lacerda, A. E., Kirsch, G. E., Brown, A. M. & Bruening-Wright, A. The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. J. Pharmacol. Toxicol. Methods. 61, 277-286 (2010).
17. Philips, J. A. et al. Torsades de pointes associated with voriconazole use. Transpl. Infect. Dis. 1, 33-36 (2007).
18. Towart, R. et al. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening? J. Pharmacol. Toxicol. Methods. 60, 1-10 (2009).
19. Kuryshev, Y.A. et al. Pentamidine-induced longQTsyndrome and blockofhERG trafficking. J. Pharmacol. Exp. Ther. 312, 316-323 (2005).
20. Liu, T. et al. Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm. 3, 948-956 (2006). (Pubitemid 44103507)
21. Valentin, J. P., Hoffmann, P., De Clerck, F., Hammond, T. G. & Hondeghem, L. Review of the predictive value of the Langendorff heart model (Screenit system) in assessingthe proarrhythmic potential of drugs. J. Pharmacol. Toxicol. Methods. 49, 171-81 (2004). (Pubitemid 38686655)
22. Gintant, G. A., Limberis, J. T., McDermott, J. S., Wegner, C. D. & Cox, B. F. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J. Cardiovasc. Pharmacol. 37, 607-618 (2001). (Pubitemid 32377916)
23. Thomsen, M. B. et al. Sudden cardiac death in dogs with remodeled hearts is associated with larger beat-to-beat variability of repolarization. Basic Res. Cardiol. 100, 279-287 (2005). (Pubitemid 41348819)
24. Schuster, D., Laggner, C. & Langer, T. Why Drugs Fail-A StudyonSide Effects in New Chemical Entities. Current Pharmaceutical Design, 11, 3545-3559 (2005). (Pubitemid 41300759)
25. Venables, W. N. & Ripley, B. D. Modern Applied Statistics with S, Fourth Edition, Springer: New York, USA, 2002.
26. Hosmer, D.W. & Lemeshow, S. Applied Logistic Regression. John Wiley and Sons, Hoboken, New Jersey, USA, 2000.
27. Zweig, M. H. & Campbell, G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin. Chem. 39, 561-577 (1993). (Pubitemid 23118304)
28. Youden, W. J. Index for rating Diagnostic tests. Cancer. 3, 32-35 (1950).
29. DeLong, E.R., DeLong, D.M. & Clarke-Pearson, D. L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 44, 837-845 (1988).
30. Hanley, J. A. & Hajian-Tilaki, K. O. Sampling variability of nonparametric estimates of the areas under receiver operating characteristic curves: an update. Acad. Radiol. 4, 49-58 (1997). (Pubitemid 127469844)